9 results about "Interleukin 12" patented technology

Activatable interleukin 12 (IL12) fusion proteins and constructs are disclosed herein that contain at least one of the following structures: N'-DD-L1-MM-L2-IL12-C', C'-DD-L1-MM-L2-IL12-N', N'-DD-L1-IL12-L2-MM-C', C'-DD-L1-IL12-L2-MM-N', wherein L1 is a first linker or is absent; L2 is a second linker; DD is a dimerization domain; MM is a masking moiety; IL12 comprises an IL12α (p35) domain and an IL12β (p40) domain; N' is an amino terminus of the activatable IL12 fusion protein; and C' is a carboxy terminus of the activatable IL12 fusion protein, wherein at least one of L1 and L2 comprises a cleavable moiety (CM); or a first IL12 subunit and a second IL12 subunit; at least one of a first linking region (LR1) and a second linking region (LR2); and a half-life extending moiety (EM), wherein at least one of the LR1 and the LR2 comprises a cleavable moiety (CM); or dimers thereof.

Pharmaceutical compositions comprising anti-interleukin 12 (IL-12) interleukin 23 (IL-23) antibodies are described. The pharmaceutical compositions may comprise molecular attributes, such as oxidation of light chain W32, isoaspartic acid at heavy chain position D55; high molecular weight species such as dimers and / or oligomers, high mannose, sialylation, or acidic peak species. Method comprising administering the pharmaceutical compositions are described. Methods of manufacturing the pharmaceutical compositions are described.

The present disclosure relates to multifunctional molecules comprising masked interleukin 12 and methods of making and using the same. In certain embodiments, the multifunctional molecules disclosed herein comprise a cleavable linker.

The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a threat to global public health. While some individuals exhibit mild symptoms, others develop severe disease leading to severe lymphopenia and death. Provided herein are methods for determining whether a subject suffering from a SARS-Cov-2 infection is more likely to suffer from severe or mild disease. Also provided are methods for predicting whether a subject suffering from a SARS-Cov-2 infection with mild disease will progress to more severe disease and methods for treating patients having an infection via SARS-Cov-2 and related family members.

Provided is a cytokine combination useful for treating a tumor and / or preventing recurrence or metastasis of the tumor. The cytokine combination with at least three cytokines selected from the following groups: interleukin 12 (IL12) or a functional variant thereof, granulocyte-macrophage colony-stimulating factor (GMCSF) or a functional variant thereof, FMS-like tyrosine kinase 3 ligand (FLT3L) or a functional variant thereof, interleukin 2 (IL2) or a functional variant thereof, interleukin 15 (IL15) or a functional variant thereof, interleukin 21 (IL21) or a functional variant thereof, and interleukin 7 (IL7) or a functional variant thereof. Also provided is a nucleic acid molecule encoding the cytokine combination and a vector thereof, a cell, a pharmaceutical composition, and a application thereof for the manufacture of a drug for treating the tumor and / or preventing recurrence or metastasis of the tumor.

Disclosed are an interleukin 12 mutant and the use thereof, belonging to the technical field of genetic engineering. The IL-12 mutant protein comprises a mutated P40 subunit and / or a mutated P35 subunit, wherein the mutated P40 subunit is generated by means of mutating a wild-type P40 subunit at the following positions: positions 37, 38, 39, 40, 81, 82, 106, 108, 114, 115 or / and 219, and the mutation eliminates or reduces the binding affinity of the wild-type P40 subunit for IL-12Rβ1; and the mutated P35 subunit is generated by means of mutating a wild-type P35 subunit at the following positions: positions 72, 151 or / and 190, and the mutation eliminates or reduces the binding affinity for IL-12Rβ2. The IL12 mutant protein and fusion protein can significantly improve a therapeutic effect by means of reducing toxicity and enhancing tumor targeting.

The present invention relates to muteins of the α-subunit of human Interleukin 12 as well as to muteins of the human Interleukin 12 comprising said α-subunit (p35) and a β-subunit. Further, the present invention is directed to a cDNA or DNA nucleic acid molecule or mRNA nucleic acid molecule comprising a nucleotide sequence encoding said muteins according to the present invention, to an engineered cell or virus, a recombinant protein, a fusion-protein, an immune modulator, a pharmaceutical composition comprising any of the muteins according to the present invention. Further, the present invention related to the use of the mutein for the manufacture of a medicament for treating a disease in a mammal, the mutein of the present invention for use as a medicament, a method of treating an Interleukin 12-mediated disease in a mammal, and a method for producing the mutein according to the present invention.

This disclosure relates to a multifunctional molecule containing a shielding interleukin 12, and to methods for fabricating and using the same. In certain embodiments, the multifunctional molecule disclosed herein includes a cleavable linker.

The present invention relates to muteins of the α-subunit of human Interleukin 12 as well as to muteins of the human Interleukin 12 comprising said α-subunit (p35) and a β-subunit. Further, the present invention is directed to a cDNA or DNA nucleic acid molecule or mRNA nucleic acid molecule comprising a nucleotide sequence encoding said muteins according to the present invention, to an engineered cell or virus, a recombinant protein, a fusion-protein, an immune modulator, a pharmaceutical composition comprising any of the muteins according to the present invention. Further, the present invention related to the use of the mutein for the manufacture of a medicament for treating a disease in a mammal, the mutein of the present invention for use as a medicament, a method of treating an Interleukin 12-mediated disease in a mammal, and a method for producing the mutein according to the present invention.